Previous close | 10.14 |
Open | 10.08 |
Bid | 10.70 x N/A |
Ask | 10.76 x N/A |
Day's range | 10.08 - 10.08 |
52-week range | 9.45 - 27.72 |
Volume | |
Avg. volume | 17 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Despite a flat performance over the last week, the United States stock market has seen an impressive 24% increase over the past year with earnings expected to grow by 15% annually. In such a thriving environment, undervalued small-cap stocks like AtriCure, which show promising insider actions, could present intriguing opportunities for investors looking for potential growth.
Amid a robust surge in the U.S. stock market, with major indices like the S&P 500 and Nasdaq 100 reaching new highs largely due to mega-cap tech companies, smaller cap stocks often present unique opportunities for discerning investors. Given the current economic climate and insider transactions, understanding what makes a small-cap stock potentially undervalued could be particularly timely.
Leggett & Platt, Incorporated ( NYSE:LEG ) is about to trade ex-dividend in the next four days. The ex-dividend date is...